Understanding how pancreatic cancer cells resist chemotherapy
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer
['FUNDING_OTHER'] · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · NIH-11181795
This study is looking at why some pancreatic cancer patients don’t respond well to chemotherapy, using tiny lab-grown versions of their tumors to find out how different factors might affect treatment success, with the hope of creating better, personalized treatment plans for everyone.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR (nih funded) |
| Locations | 1 site (OKLAHOMA CITY, UNITED STATES) |
| Trial ID | NIH-11181795 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms behind chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC) using patient-derived organoids (PDOs). By creating a 3D culture system, researchers can closely mimic the tumor environment and study how different metabolic pathways affect the cancer's response to treatments like FOLFIRINOX. The goal is to identify specific metabolic profiles that correlate with either sensitivity or resistance to chemotherapy, potentially leading to more effective treatment strategies tailored to individual patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are undergoing or considering chemotherapy treatment.
Not a fit: Patients with non-pancreatic cancers or those who are not candidates for chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for pancreatic cancer patients by identifying which therapies are most likely to be effective based on individual tumor characteristics.
How similar studies have performed: Other research has shown promise in using patient-derived models to study cancer treatment responses, indicating that this approach could yield valuable insights.
Where this research is happening
OKLAHOMA CITY, UNITED STATES
- UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR — OKLAHOMA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SINGH, PANKAJ KUMAR — UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- Study coordinator: SINGH, PANKAJ KUMAR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Patient, Cancers